Exenatide once weekly for the treatment of type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 359-367

  Malone, James ^a   Trautmann, Michael ^a   Wilhelm, Ken ^b   Taylor, Kristin ^b   Kendall, David M ^c  

^a ELI LILLY AND COMPANY   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

Exenatide; Glucagon like peptide 1; Glucagon like peptide 1 receptor agonist; Incretin; Obesity; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; AVE 0010; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; VENOM;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD INTAKE; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACODYNAMICS; REVIEW; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMISTRY; DRUG TOLERANCE; METABOLISM; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG TOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 67449086488     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902766802     Document Type: Review

References (57)

1. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995;44:1249-1258
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
3. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65 • Landmark study with long-term clinical data demonstrating the progressive nature of T2DM.
4. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
5. Prevalence of Diabetes Worldwide: Country and Regional Data. World Health Organization. Available from: http://www.who.int/diabetes/facts/world-figures/ en/.2008. [Last accessed 24 October 2008]
6. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625 (Pubitemid 40770750)
7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
8. Anderson BJ. Diabetes self-care: lessons from research on the family and broader contexts. Curr Diab Rep 2003;3:134-140 (Pubitemid 38899138)
9. Stonehouse AH, Okerson T, Kendall DM, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diab Rev 2008;4:101-109
10. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007;23:905-917 (Pubitemid 46631494)
11. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303 (Pubitemid 29383658)
12. Maggio C, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2008;32:805-822 (Pubitemid 38029982)
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157 (Pubitemid 46711096)
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
15. Stonehouse AH, Holcombe JH, Kendall DM. Management of Type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother 2006;7:2095-2105
16. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520 (Pubitemid 28084232)
17. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005;128:135-148 (Pubitemid 40380914)
18. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30 • One of the first clinical studies to demonstrate the glucoregulatory actions of longer-term GLP-1 treatment in patients with T2DM. (Pubitemid 34233752)
19. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-835
20. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131
21. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005;22:1016-1023 (Pubitemid 41025998)
22. Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-423 (Pubitemid 44620484)
23. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
24. Ratner RE, Rosenstock J, Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin. Diabetes 2008 57:A129 [Abstract 433-P]
25. Balena R, Ratner R, Berria R, et al. Eight weeks of treatment with the long acting human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study. Diabetes 2008;57:A33 [abstract 108-OR]
26. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting glucagon-like peptide 1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-4817
27. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568 (Pubitemid 44841980)
28. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-180 (Pubitemid 46269371)
29. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-428 (Pubitemid 44047965)
30. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35 • One of three long-term registration trials for exenatide BID in patients with T2DM, demonstrating that exenatide BID as adjunctive therapy to a sulfonylurea improved glycemic control and was generally well tolerated.
31. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100 • One of three long-term registration trials for exenatide BID in patients with T2DM, demonstrating that exenatide BID as adjunctive therapy to metformin improved glycemic control and was generally well tolerated.
32. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91 • One of three long-term registration trials for exenatide BID in patients with T2DM, demonstrating that exenatide BID as adjunctive therapy to combined metformin and a sulfonylurea improved glycemic control and was generally well tolerated. (Pubitemid 40616617)
33. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286 (Pubitemid 351160260)
34. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108-4115 (Pubitemid 27078475)
35. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5 • Initial publication to describe that exendin-4 has insulinotropic actions on pancreas.
36. Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-589 (Pubitemid 32433049)
37. Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999;20:1057-1062 (Pubitemid 29229474)
38. BYETTA® (exenatide) injection prescribing information, 2008
39. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93 •• Dose ranging trial that established the pharmacokinetics, safety and dose to evaluate effectiveness for exenatide QW. (Pubitemid 46871159)
40. Drucker DJ, Buse J, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008 372:1240-50 •• Long-term comparator trial of exenatide BID and QW; demonstrated that sustained exposure to exenatide resulted in an improved glycemic control and tolerability profile relative to BID dosing.
41. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85 • Demonstrated that exenatide BID as adjunctive therapy to a thiazolidinedione, or combined thiazolidinedione and metformin, improved glycemic control and was generally well tolerated.
42. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-1460
43. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69 • Demonstrated that exenatide BID provides similar improvements in HbA1c compared to insulin glargine, with lower risk of hypoglycemia, and weight gain.
44. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67 • Demonstrated that exenatide BID provides similar improvements in HbA1c compared with biphasic insulin aspart, with lower risk of hypoglycemia, and weight reduction.
45. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52 • First head-to-head study comparing exenatide BID and the DPP-4 inhibitor sitagliptin in a short-term study focused on mechanisms of action. Patients on exenatide BID experienced significantly lower post-meal glucose levels, improved measures of beta cell function and decreased food intake.
46. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447 (Pubitemid 44349236)
47. Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33:336-344
48. Noel RA, Braun DK, Patterson R, Bloomgren G. Estimated incidence of acute pancreatitis in patients with type 2 diabetes. Pharmacoepidemiol Drug Saf 2008;17:S1-294
49. Bain SC, Stephens JW. Exenatide and pancreatitis: an update. Expert Opin Drug Saf 2008;7:643-644
50. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-1625 (Pubitemid 40471792)
51. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132 (Pubitemid 41070972)
52. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005;146:2069-2076 (Pubitemid 40396918)
53. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-5997 (Pubitemid 41606516)
54. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005;5:275-286 (Pubitemid 40663134)
55. Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-1570 (Pubitemid 33639596)
56. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-2276 (Pubitemid 30395416)
57. Diabetes Atlas. Third edition©. International Diabetes Foundation, 2006.